Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.

A similar survival analysis was performed on the TCGA-BLCA cohort, and the survival trend was similar to that for the ICI cohort but did not reach statistical significance (log-rank test, HR 0.85 [95% CI 0.63–1.14], p = 0.281, Additional file 4 : Figure S4E).

also in 111,027 other papers